Caring for Patients with Severe Asthma: Evolving Best Practices to Optimize Outcomes
This CME-accredited Clinical Research UpdatesTM program is intended for allergists/clinical immunologists, pulmonologists, and other healthcare providers involved in the identification, evaluation, and treatment of patients with severe asthma. During the activity, a panel of expert faculty discuss and debate the latest evidence for severe asthma phenotypes, the clinical utility of various disease biomarkers, and the profiles of current and emerging biologic therapies, with a focus on individualizing treatment plans. Faculty also incorporate the perspectives of patients with asthma, including the burdens of severe disease, hidden challenges to good long-term outcomes, and the benefits of shared decision-making.
This activity has been designed to meet the educational needs of clinical immunologists, pulmonologists, and other clinician specialists involved in the management of patients with severe asthma.
Upon completion of this activity, participants will be better able to do the following:
- Describe the pathophysiologic underpinnings of severe asthma, including current insights into disease subtypes and therapeutic targets for biologic medications
- Identify patients with severe asthma based on an understanding of epidemiologic data and comprehensive evaluations of symptoms, phenotypes, and treatment history
- Compare the mechanisms of action and clinical profiles of cytokine-targeting biologic medications in the treatment of severe asthma
- Tailor therapy for patients with severe asthma to address ongoing symptoms, biomarker evaluations, exacerbation risks, and treatment responses
- Dialogue with patients with severe asthma about therapeutic choices, asthma action plans, and treatment adherence
Eugene R. Bleecker, MD
Sidney S. Braman, MD, FCCP
Richard J. Martin, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter|
Relationship Identified With:
Eugene R. Bleecker, MD
Nothing to disclose.
|Sidney S. Braman, MD, FCCP|
Speakers’ Bureau: AstraZeneca; Boehringer Ingelheim GmbH; Genentech, Inc.
|Richard J. Martin, MD|
Consultant/Advisor: AstraZeneca; PMD Healthcare
Research Grant: CHIESI Farmaceutici S.p.A.; National Heart, Lung, and Blood Institute Asthma NetworkRoyalties/Patents: UpToDate, Inc.
Non-faculty: Rose O’Connor, PhD; Jim Kappler, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouses/life partners have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from AstraZeneca.
Jointly provided by the Elsevier Office of Continuing Medical Education and Integritas Communications.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Integritas Communications. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Integritas Communications, and AstraZeneca do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician